Sodium Hydroxide → 2-[benzothiazol-2(3H)-ylidene]-2-[4-tert-butyl-6-(trifluoromethyl)pyrimidin-2-yl]acetamide
반응식
[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[NH:3][C:2]1=[C:10]([C:13]1[N:18]=[C:17]([C:19]([CH3:22])([CH3:21])[CH3:20])[CH:16]=[C:15]([C:23]([F:26])([F:25])[F:24])[N:14]=1)[C:11]#[N:12].[OH-:27].[Na+]>S(=O)(=O)(O)O>[S:1]1[C:5]2[CH:6]=[CH:7][CH:8]=[CH:9][C:4]=2[NH:3][C:2]1=[C:10]([C:13]1[N:18]=[C:17]([C:19]([CH3:21])([CH3:22])[CH3:20])[CH:16]=[C:15]([C:23]([F:24])([F:25])[F:26])[N:14]=1)[C:11]([NH2:12])=[O:27]참가 물질
4
실험 절차
2-[Benzothiazol-2(3H)-ylidene]-2-[4-tert-butyl-6-(trifluoromethyl)pyrimidin-2-yl]acetonitrile (150 mg, 0.39 mmol) was dissolved in concentrated sulfuric acid (1.5 mL) and stirred at room temperature overnight. The mixture was cooled to 0° C., poured over ice, and neutralized with 50% aqueous sodium hydroxide. The product was partially extracted into chloroform, and dried to a brown solid (57 mg), which was purified by reverse phase preparative HPLC to give 2-[benzothiazol-2(3H)-ylidene]-2-[4-tert-butyl-6-(trifluoromethyl)pyrimidin-2-yl]acetamide (13 mg) as a yellow solid.
후처리
- temperatureThe mixture was cooled to 0° C.
- additionpoured over ice
- extractionThe product was partially extracted into chloroform
- dry with materialdried to a brown solid (57 mg), which
- customwas purified by reverse phase preparative HPLC
출처 및 근거
- ORD 기록
- ord-737e1bb1a0294ef38b3e72aed09ce5cf
- 출처 데이터셋
- uspto-grants-2012_03
- 특허 번호
- US08129396B2
반응 노트
불러오는 중…